Is Teladoc Health a Good Value Stock Now?

TL;DR

Teladoc Health, now valued at $4.6 billion after an 80% stock decline, is showing potential as a value stock. Despite still operating at a loss, the company's Q3 revenue of $611.4 million indicates 17% year-over-year growth, and its Q4 guidance suggests steady revenue between $625 and $640 million, hinting at improving financials.

Transcript

so I I can't believe I'm gonna say this with a straight face and actually mean it but is teledoc Health now a value stock after all this time what is going on investors hopefully you guys are doing well out there if you remember my videos on teledoc health they mirrored a little bit of our Intel videos and our plug power videos I absolutely invisce... Read More

Key Insights

• 🥺 Teledoc Health's stock has decreased by over 80% in the past year, leading to a 4.6 billion dollar valuation.
• 💓 The company's Q3 earnings beat expectations, with revenue of 611.4 million dollars and 17% growth year over year.
• 🖕 Despite not being profitable, Teledoc Health's mid-teens revenue growth and improved margins indicate positive prospects.

Questions & Answers

Q: Is Teledoc Health now considered a value stock?

Teledoc Health's significant decrease in market caps, improved financials, and potential for mid-teens revenue growth make it a potential value stock worth considering.

Q: How did Teledoc Health perform in its Q3 earnings?

Teledoc Health reported Q3 revenue of 611.4 million dollars, beating expectations and showing a 17% growth year over year.

Q: What is the Q4 revenue guidance for Teledoc Health?

Teledoc Health expects Q4 revenue between 625 and 640 million dollars, aligning with average analyst estimates.

Q: Is Teledoc Health expected to achieve profitability?

While Teledoc Health is not projected to be profitable in the next two years from a gap perspective, its mid-teens revenue growth and improved financials suggest it is on the path to profitability.

Summary & Key Takeaways

• Teledoc Health reported Q3 earnings of 611.4 million dollars, beating expectations and showing a 17% growth year over year.

• Q4 guidance suggests expected revenue between 625 and 640 million dollars, aligning with average analyst estimates.

• While the company is still not profitable, its mid-teens revenue growth and improved margins indicate positive prospects.